Voice your opinion on congressional bill HR2855-117 and let lawmakers know your stance with UnPac!

Main Subject: Health

Star Rating for Biosimilars Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.

The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

HR5260-117, HR5237-117,

House committee actions Actions

Committee
Apr. 27 2021	Referred to the Subcommittee on Health.
Apr. 26 2021	Referred to the Subcommittee on Social Security. Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral

Apr. 26
2021

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Library of Congress Actions

IntroReferral
Apr. 26 2021	Introduced in House Introduced in House

House bill HR2855-117

Star Rating for Biosimilars Act

Promote the cause!

Or use this QR code